At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PCRX Pacira Pharmaceuticals
Market Closed 11-01 16:00:00 EDT
16.57
-0.03
-0.18%
盘后16.57
+0.000.00%
16:20 EDT
High17.07
Low16.40
Vol466.98K
Open16.79
D1 Closing16.60
Amplitude4.04%
Mkt Cap764.32M
Tradable Cap756.04M
Total Shares46.13M
T/O7.77M
T/O Rate1.02%
Tradable Shares45.63M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Pacira Biosciences Inc expected to post earnings of 70 cents a share - Earnings Preview
Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.